In vivo dosimetry with semiconductors in medium dose rate (MDR) brachytherapy for cervical cancer

Allahverdi, Mahmoud; Jaberi, Ramin; Aghili, Mehdi; Ghahremani, Fatemeh; Geraily, Ghazale

doi:10.1007/s11604-012-0160-x

Cited by 6 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eventually, the high standard deviation for the absorbed dose differences from IVD during the current study can be due to several factors, such as the BT steep dose gradient, inaccurate localization of the control points for TLDs in TPS, and uncertainties related to the intra‐fractional variations in the relative position of applicators to the OARs. Other potential factors contributing to the absorbed dose differences during GYN BT are variation in size, shape, and position of the OARs (e.g., the rectal peristaltic motion) and applicator geometrical shift during the gap time between the CT scanning and their treatment delivery 9,11,27 …”

Section: Discussionmentioning

confidence: 99%

“…Other potential factors contributing to the absorbed dose differences during GYN BT are variation in size, shape, and position of the OARs (e.g., the rectal peristaltic motion) and applicator geometrical shift during the gap time between the CT scanning and their treatment delivery. 9,11,27 There is a lack of online organ motions verification during the treatment delivery in most of the BT departments. Therefore, intra-fractional variations of organs and dosimeters' position to the applicators are essential factors of BT uncertainties.…”

Section: Discussionmentioning

confidence: 99%

“…IVD is a radiation measurement taken while the patient is being treated and contains information about the absorbed dose. IVD is the practical method for treatment quality control to specify the treatment procedure accuracy and assess the absorbed dose delivery 4,7–9 . IVD has been used in BT by a variety of dosimeters and measurement technologies, such as thermoluminescent dosimeters (TLDs), 7,10 diodes, 11,12 MOSFETs, 3,13 and plastic scintillation detectors 14 .…”

Section: Introductionmentioning

confidence: 99%

“…IVD is the practical method for treatment quality control to specify the treatment procedure accuracy and assess the absorbed dose delivery. 4,[7][8][9] IVD has been used in BT by a variety of dosimeters and measurement technologies, such as thermoluminescent dosimeters (TLDs), 7,10 diodes, 11,12 MOSFETs, 3,13 and plastic scintillation detectors. 14 Thermoluminescent dosimetry has been determined as a suitable system for dosimetry in BT.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

3D in vivo dosimetry of HDR gynecological brachytherapy using micro silica bead TLDs

Jaberi

Babaloui

Siavashpour

et al. 2022

J Applied Clin Med Phys

Self Cite

View full text Add to dashboard Cite

This study aimed to evaluate the feasibility of defining an in vivo dosimetry (IVD) protocol as a patient-specific quality assurance (PSQA) using the bead thermoluminescent dosimeters (TLDs) for point and 3D IVD during brachytherapy (BT) of gynecological (GYN) cancer using 60 Co high-dose-rate (HDR) source. Methods: The 3D in vivo absorbed dose verification within the rectum and bladder as organs-at-risk was performed by bead TLDs for 30 GYN cancer patients. For rectal wall dosimetry, 80 TLDs were placed in axial arrangements around a rectal tube covered with a layer of gel. Ten beads were placed inside the Foley catheter to get the bladder-absorbed dose. Beads TLDs were localized and defined as control points in the treatment planning system (TPS) using CT images of the patients. Patients were planned and treated using the routine BT protocol. The experimentally obtained absorbed dose map of the rectal wall and the point dose of the bladder were compared to the TPSs predicted absorbed dose at these control points. Results: Relative difference between TPS and TLDs results were −8.3% ± 19.5% and −7.2% ± 14.6% (1SD) for rectum-and bladder-absorbed dose, respectively.Gamma analysis was used to compare the calculated with the measured absorbed dose maps. Mean gamma passing rates of 84.1%, 90.8%, and 92.5% using the criteria of 3%/2 mm, 3%/3 mm, and 4%/2 mm were obtained, respectively. Eventually, a "considering level" of at least 85% as pass rate with 4%/2-mm criteria was recommended. Conclusions: A 3D IVD protocol employing bead TLDs was presented to measure absorbed doses delivered to the rectum and bladder during GYN HDR-BT as a reliable PSQA method. 3D rectal absorbed dose measurements were performed. Differences between experimentally measured and planned absorbed dose maps were presented in the form of a gamma index, which may be used as a warning for corrective action.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

3D in vivo dosimetry of HDR gynecological brachytherapy using micro silica bead TLDs

Jaberi

Babaloui

Siavashpour

et al. 2022

J Applied Clin Med Phys

Self Cite

View full text Add to dashboard Cite

show abstract

“…The PTW-Freiburg Model 9112 (PTW 9112) semiconductor diode detector array has been developed for rectal IVD during brachytherapy treatment. This commercially available diode has been extensively used in several studies for real-time rectal dose measurement using Cs-137, Ir-192, and Co-60 sources, demonstrating the detector's dependability for overall treatment checks (Waldhäusl et al, 2005;Tanderup et al, 2006;Allahverdi et al, 2013;Zaman et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

In-vivo Comparison of Planned and Measured Rectal Doses during Cobalt-60 HDR CT-based Intracavitary Brachytherapy Applications of Cervical Cancer Using the PTW 9112 Semiconductor Probe

Johan

Lobo

Athiyamaan

et al. 2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

Correlation analysis of CT-based rectal planning dosimetric parameters with in vivo dosimetry of MOSkin and PTW 9112 detectors in Co-60 source HDR intracavitary cervix brachytherapy

2021

View full text Add to dashboard Cite

In vivo dosimetry with semiconductors in medium dose rate (MDR) brachytherapy for cervical cancer

Abstract: The main reason for the differences between the measured and calculated doses was patient movement. To reduce the risk of large errors in the dose delivered, in vivo dosimetry should be performed in addition to treatment planning system computations.

Cited by 6 publications

References 9 publications

3D in vivo dosimetry of HDR gynecological brachytherapy using micro silica bead TLDs

3D in vivo dosimetry of HDR gynecological brachytherapy using micro silica bead TLDs

In-vivo Comparison of Planned and Measured Rectal Doses during Cobalt-60 HDR CT-based Intracavitary Brachytherapy Applications of Cervical Cancer Using the PTW 9112 Semiconductor Probe

Correlation analysis of CT-based rectal planning dosimetric parameters with in vivo dosimetry of MOSkin and PTW 9112 detectors in Co-60 source HDR intracavitary cervix brachytherapy

Contact Info

Product

Resources

About